Safety and Efficacy of RVU120 Combined With Venetoclax for Treatment of Relapsed/Refractory AML
A phase 2 trial of Venetoclax in acute myeloid leukaemia, run by Ryvu Therapeutics SA, now recruiting.
Overview
Safety and Efficacy of RVU120 Combined With Venetoclax for Treatment of Relapsed/Refractory AML is a phase 2 interventional study registered as NCT06191263 by Ryvu Therapeutics SA, with 98 participants planned, started 2024-01-05 and due to reach its primary completion in 2027-08. Interventions recorded: RVU120 and Venetoclax.
Similar pages
not linked directly; found by shared links- TrialRVU120 for Treatment of Anemia in Patients With Lower-risk Myelodysplastic Neoplasms
Shares Ryvu Therapeutics and the tag pipeline.
- TrialA Phase 2 Study of MAX-40279 Combined With Venetoclax and Azacitidine in Unfit Newly Diagnosed Acute Myeloid Leukemia
Shares Venetoclax, Acute myeloid leukaemia and the tag pipeline.
- TrialDFP-10917 in Combination With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia
Shares Venetoclax, Acute myeloid leukaemia and the tag pipeline.
- TrialAB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Shares Venetoclax, Acute myeloid leukaemia and the tag pipeline.
- TreatmentMEN1703
Shares Ryvu Therapeutics and the tag pipeline.
- TrialA Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia
Shares Venetoclax, Acute myeloid leukaemia and the tag pipeline.
- TrialIMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia
Shares Venetoclax, Acute myeloid leukaemia and the tag pipeline.
- TrialA Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)
Shares Venetoclax, Acute myeloid leukaemia and the tag pipeline.